ConductScience.org, home

Paper25670366

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

Krauss RM and 4 others. J Clin Lipidol, 2015. Cited by 17 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. Papers, record 25670366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25670366

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
PubMed
Journal
J Clin Lipidol
PubMed
Year
2015
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.49
iCite
Revised in PubMed
2018-12-02
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Krauss RMRonald M
2Pinto CACathy Anne
3Liu YYang
4Johnson-Levonas AOAmy O
5Dansky HMHayes M

Source PubMed

Download CSV of authors

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anticholesteremic AgentsMajor topic
DyslipidemiasMajor topic
Heptanoic AcidsMajor topic
Hydroxymethylglutaryl-CoA Reductase InhibitorsMajor topic
OxazolidinonesMajor topic
PyrrolesMajor topic
Adolescent
Adult
Aged
Apoproteins
Atorvastatin
Cholesterol Ester Transfer Proteins
Cholesterol, LDL
Double-Blind Method
Drug Administration Schedule
Female
Humans
Lipoproteins, HDL
Lipoproteins, LDL
Lipoproteins, VLDL
Male
Middle Aged
Placebo Effect
Treatment Outcome
Triglycerides
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 DK026743NIDDK NIH HHSUnited StatesP30DK026743PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00325455MK0859 Dose-Ranging Study (0859-003)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119185645Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.Am Heart J2009https://conductscience.org/library/papers/19185645PubMed
222130116Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.Clin Pharmacol Ther2012https://conductscience.org/library/papers/22130116PubMed
322180633Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.J Lipid Res2012https://conductscience.org/library/papers/22180633PubMed
412235168Metabolic origins and clinical significance of LDL heterogeneity.J Lipid Res2002https://conductscience.org/library/papers/12235168PubMed
515198488Use of the false discovery rate for evaluating clinical safety data.Stat Methods Med Res2004https://conductscience.org/library/papers/15198488PubMed
66403642Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.J Lipid Res1983https://conductscience.org/library/papers/6403642PubMed
78409761Plasma cholesteryl ester transfer protein.J Lipid Res1993https://conductscience.org/library/papers/8409761PubMed
88305409
A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma.
Arterioscler Thromb1994https://conductscience.org/library/papers/8305409PubMed
98640407Differences in receptor binding of LDL subfractions.Arterioscler Thromb Vasc Biol1996https://conductscience.org/library/papers/8640407PubMed
1016574893Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.Arterioscler Thromb Vasc Biol2006https://conductscience.org/library/papers/16574893PubMed
1118515257Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis.Clin Chem2008https://conductscience.org/library/papers/18515257PubMed

Download CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
41549108Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials.Daru2026https://conductscience.org/library/papers/41549108PubMed
37047642Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes-A Comprehensive Review.Int J Mol Sci2023https://conductscience.org/library/papers/37047642PubMed
34829807Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options.Biomedicines2021https://conductscience.org/library/papers/34829807PubMed
31475865Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.Eur J Prev Cardiol2020https://conductscience.org/library/papers/31475865PubMed
28961179Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?Diseases2017https://conductscience.org/library/papers/28961179PubMed
28314859Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.J Lipid Res2017https://conductscience.org/library/papers/28314859PubMed
26408274
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Circulation2015https://conductscience.org/library/papers/26408274PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ANACETRAPIBCHEMBL1800807Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1800807

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25670366

GET https://conductscience.org/api/papers/v1/25670366/authors